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Which is the cause of DMD? 
DMD is a is an X-linked recessive disorder caused by mutations in dystrophin gene, that provokes a non-functional protein. When this mutations appear 
protein loses its capacity to bind internal cytoskeleton to extracellular matrix in muscular tissue. DMD patients suffer from muscular degeneration, that 
over time becomes life-threatening. In contrast, BMD patients develop milder and later symptoms as the mutations lead to a truncated but partially 
functional dystrophin 
How does CRISPR/Cas9 technology work? 
CRISPR/Cas9 is a genome editing tool that uses a guide RNA (gRNA) and a specific nuclease 
(Cas9) to cleave a targeted sequence. The result will be a double-strand break in the DNA 
sequence, which the cell will try to repair by either HDR (homology-directed repair) or NHEJ 
(non-homologous end-joining), performing the genome edition.  
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In situ muscle force test 
(Aurora) shows  a 
significant improvement 
in both increase in muscle 
force and a decrease in 
muscle  force drop in 
treated mice as seen in 
the graphics.  
RT-PCR from four mice after AAV-retraorbital injection shows the presence of an excised 
band in time, demonstrating that the CRISPR/Cas9 method had excised exon 23 
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The Western blot analysis from Nelson et al. confirmed the presence of dystrophin after the treatment as 
shown in the positive controls (+). Moreover, the intensity quantification confirms a presence of at least 6% 
of dystrophin in TA muscle and 12% in heart muscle.  
Large deletion but in frame Small deletion but out-of-frame 
RT-PCR shows an only band in non-treated animals, in contrast to AAV-CRISPR/Cas9 treated mice that show 
two bands, the lower corresponding to the missing defective exon 23.  
RT-PCR shows again a non excised band of 700 pb in all mice and in animals treated with 
AAV-Dmd an additional 500 bp band corresponding to the excised exon.  
A Western blot was performed to see the dystrophin presence, in this case with 4 mice 
treated by retraorbital injection at 8 weeks, comparing skeletal TA and heart muscles.  
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CRISPR/Cas9 exon skipping NHEJ repair 
In situ muscle force 
test (Aurora) from 
Tabebordbar shows  a  
very slight 
improvement of 
treated mice in 
muscle force and a 
decrease in muscle  
force drop.  
The Western blot assay confirmed the presence of dystrophin after the treatment as shown 
in 7 mice treated with Dmd gRNAs. The intensity quantification confirms the presence of 
dystrophin in both heart and TA muscle, compared with the WT and the negative control.  
Long et al. performed a grip 
strength test in male and 
female mice 4 weeks after 
intraperitoneal injection and 
the results show a significant 
improvement of the muscle 
force.   
• This novel approach is optimistic as results have shown a significant recovery of dystrophin levels and muscle force. 
• The fact of the use of CRISPR/Cas9 enables this therapy to be easier and faster than other therapies used in DMD.  
• Off-target effects are a concern and need to be accurately analysed in order to guarantee more effective and safer results in this therapy.  
• Another concern is vector delivery and production, as it is now one of the main burden in gene therapy, so there should be more study in 
vector optimization and production.  
• Bioethical implications need to be considered when reaching into Clinical Phase, as the patients involved are being children and this is a 
great deal.  
An immunofluorescence analysis was performed in heart and TA tissue after retraorbital 
injection and the results show a considerable increase in the presence of dystrophin comparing 
with mdx phenotype    
The immunofluorescence comparison between WT, saline (Mdx non-treated) and treated mice show that 
after AAV-CRISPR intraperitoneal injection, heart and TA have significantly recovered dystrophin.  
The immunofluorescence assay from two treated mice show an increase in the presence of 
dystrophin in both heart and skeletal muscle cells in comparison to non-treated (vehicle). 
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